Evaluation and verification of serological activity markers in systemic lupus erythematosus

Project

Evaluation and verification of serological activity markers in systemic lupus erythematosus

Automatically Closed · 2015 until 2018

Schmiedeberg Kristin, von Kempis Johannes

Type

Fundamental Research

Range

Monocentric project at KSSG

Units

Rheumatologie

Status

Automatically Closed

Start Date

2015

End Date

2018

Financing

KSSG

Keywords

Swiss SLE Cohort Study (SSCS), SLE, Systemic lupus erythematosus, serological activity markers

Partner

Prof. Dr. Reinhard Voll, Department of Rheumatology and Clinical Immunology, University Hospital Freiburg, Germany; Dr. méd. Camillo Ribi, Immunologue allergologue, Lausanne, Swiss SLE Cohort Study (SSCS)

Brief description/objective

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease. So far, there is little evidence for the existence of specific biologic markers reliably indicating clinical activity and a rather wide panel of unspecific markers indicating systemic and/or organ manifestation is used.
In this bicentre prospective observational cohort study, our aim is to evaluate the associations between established bio-/activation markers4 as anti-ds DNA ab and complement factors with exact determination of consumption (C1q, C3, C4, CH50) and activation (C3a, iC3b, C3d, C4d, C5a, C5b-9) and according to recent findings, factors directly linked to the pathogenesis of SLE, i.e. HMGB, INFα, NET degradation, free light chains (FLC)). We want to correlate them with clinical disease activity and damage and compare them with sex and aged matched healthy controls.